🔎 Trials Near Me

Beranda › Sarkoma Ewing › Massachusetts

Uji klinis Sarkoma Ewing di Massachusetts

6 studi untuk Sarkoma Ewing mencari peserta di lokasi di Massachusetts.

Kota di Massachusetts

Teks studi resmi (Bahasa Inggris)

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

  • Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 2 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07297979

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Dana-Farber Cancer Institute ( Site 1013), Boston
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103

Lurbinectedin in FET-Fused Tumors

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 10 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05918640

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

  • Mass General Brigham Cancer Institute, Boston
  • Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 2 Jun 2026 · NCT07197554

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Menerima pesertaFase 1/2
Usia 12 hingga 49 · Semua jenis kelamin · Diperbarui 19 Feb 2026 · NCT06709495

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.